Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cáncer de Pene / Recursos de NCI
National Cancer Institute®
Ultima Vez Modificado: 1 de mayo del 2002
1
UI - 11889702
AU - Filippov SV; Kniaz'kin IV; Anichkov NM; Zeziulin PN; Shinkarenko AV;
TI -
Bykov NM
[Spitz nevus (juvenile nevus) of the penile skin]
SO - Arkh Patol 2002 Jan-Feb;64(1):46-8
AD - I. I. Mechnikov St-Petersburg State Medical Academy, 195067,
St-Petersburg.
Compound spindle cell and epithelioid cell nevus (Spitz nevus) at the
anterior surface of the penile skin in a 31-year-old patient is
described. The histological structure of the tumor is discussed in terms
of differential diagnosis.
2
UI - 11699217
AU - Beal K; Mears JG
TI -
Short report: penile lymphoma following local injections for erectile
dysfunction.
SO - Leuk Lymphoma 2001 Jun;42(1-2):247-9
AD - Columbia University College of Physicians and Surgeons, New York, NY,
USA.
We report a case of high grade lymphoma which appeared at the site of
prior injections of medications into the shaft of the penis for erectile
dysfunction. We discuss the possible mechanisms of causation for this
unusual form of lymphoma.
3
UI - 11912379
AU - Bevan-Thomas R; Slaton JW; Pettaway CA
TI -
Contemporary morbidity from lymphadenectomy for penile squamous cell
carcinoma: the M.D. Anderson Cancer Center Experience.
SO - J Urol 2002 Apr;167(4):1638-42
AD - Department of Urology, The University of Texas M.D. Anderson Cancer
Center, Houston, Texas.
PURPOSE: Inguinal lymphadenectomy can be curative in patients with small
volume inguinal metastases and those with more significant adenopathy
responding to combination chemotherapy. However, several series
collected for 15 to 40 years attest to the significant morbidity
associated with lymphadenectomy. We reviewed our recent experience with
lymphadenectomy in patients with invasive penile cancer who were judged
to require inguinal staging and therapeutic procedures to assess the
incidence and magnitude of complications caused by this procedure,
especially in those with no palpable adenopathy (prophylactic group).
MATERIALS AND METHODS: A total of 106 lymphadenectomy procedures were
performed in 53 patients. The indications for dissection were
prophylactic in 66 (62%) patients in whom a superficial dissection alone
was completed on the ipsilateral side, therapeutic in 28 (26%) in whom
superficial, deep and ipsilateral pelvic dissections were performed, and
palliative in 12 (11%) undergoing extensive resection of inguinal and
abdominal wall tissue after chemotherapy. Minor postoperative
complications included those requiring local wound debridement in the
clinic, mild to moderate leg edema, seroma formation not requiring
aspiration and minimal skin edge necrosis requiring no therapy. Major
complications included severe leg edema interfering with ambulation,
skin flap necrosis requiring a skin graft, rehospitalization, deep
venous thrombosis, death, or reexploration or other invasive procedures
performed in the operating room. The incidence and magnitude of
complications were compared with prior reports from our center and other
series. RESULTS: A total of 41 (68%) minor and 19 (32%) major
complications occurred with the 106 dissections (31 of 53 patients,
58%). Prophylactic and therapeutic dissections were associated with a
lower incidence of complications compared with palliative dissections (p
= 0.017 to 0.049). The incidence of major complications also trended
lower in the prophylactic group compared with other indications (p =
0.05). One patient in the palliative group died of sepsis on
postoperative day 15. When compared with 3 prior series, the incidence
of skin edge necrosis in our series was significantly lower (8% versus
45% to 62%, p <0.0001). Similarly, the incidence and severity of edema
in our series were significantly lower than in a prior report from our
institution (23% versus 50%, p <0.0001). CONCLUSIONS: For select
patients undergoing prophylactic inguinal dissection to detect the
presence of microscopic metastases, the incidence and magnitude of
complications appeared acceptable in our contemporary experience.
Similarly the morbidity of therapeutic lymphadenectomy appeared
acceptable, considering the potential therapeutic benefit. However,
significant complications, including death, can be associated with
palliative groin dissection. Optimal candidates are those having a
significant response to systemic chemotherapy whose groins are grossly
uninfected.
4
UI - 11912414
AU - Ung JO; Padera RF; O'Leary MP
TI -
Angiosarcoma of the penis masquerading as a Peyronie's plaque.
SO - J Urol 2002 Apr;167(4):1785-6
AD - Division of Urology/Department of Surgery, Brigham and Women's Hospital,
Harvard Medical School, Boston, Massachusetts, USA.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Dr. Glatstein shares some of the important lessons he has conveyed upon the many oncology professionals he has trained. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

